Company / R&D Expense
10x Genomics, Inc. R&D Expense History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$238.6M
FY2025
5-year range
$83.1M / $270.3M
FY2021-FY2025
Trend
-9.8%
vs FY2024
Sector context
#31 of 110
Health Care
What the data says
At $239M, 10x Genomics, Inc.'s r&d expense ranks #31 of 110 in the Health Care sector. R&D Expense has fluctuated over the past 9 years, ranging from $32M in FY2017 to $270M in FY2023.
Based on SEC 10-K filings.
$239M in FY2025 with a 5-year CAGR of +14.1%.
Declined from $270M to $239M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +24.6%
- 5-Year CAGR
- +14.1%
- 10-Year CAGR
- -
Sector benchmark
#31 of 110 in Health CareTop 28% of 110This company $238.6M Sector average $298.2M
▼
-20.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +14.1%, indicating consistent growth.
- In FY2025, r&d expense decreased 9.8% year-over-year.
- Ranks #31 out of 110 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -29.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $238.6M | -9.8% |
| FY2024 | $264.7M | -2.1% |
| FY2023 | $270.3M | +119.1% |
| FY2022 | $123.4M | +48.5% |
| FY2021 | $83.1M | -32.6% |
| FY2020 | $123.4M | +48.5% |
| FY2019 | $83.1M | +74.8% |
| FY2018 | $47.5M | +47.8% |
| FY2017 | $32.2M | - |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026